Video

Todd Villines: Developing Reversal Agents for Newer Anticoagulants

Author(s):

The development of new novel oral anticoagulants has made a definite impact in the field in a short period of time. Work is being done to bring reversal agents into the field which can work with these new medications.

The development of new novel oral anticoagulants has made a definite impact in the field in a short period of time. Work is being done to bring reversal agents into the field which can work with these new medications.

With the newer anticoagulants having been approved up to 6 years ago there is currently only one reversal agent available for one of the medications according to Lt. Col. Todd C. Villines, MD, from Walter Reed National Military Medical Center. Villines discussed the developments in the field during the annual meeting of the American College of Cardiology. As a military doctor Villines said service members who are on anticoagulants have different rules and different roles as a result but can still serve while being aware of their medical needs.

Related Videos
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Viet Le, DMSc, PA-C | Credit: APAC
Marianna Fontana, MD, PhD: Declines in Kidney Function Frequent in ATTR-CM  | Image Credit: Radcliffe Cardiology
Orly Vardeny, PharmD | Credit: JACC Journals
© 2024 MJH Life Sciences

All rights reserved.